OTCPK:CNBI

Stock Analysis Report

China BCT Pharmacy Group

Executive Summary

China BCT Pharmacy Group, Inc., through its subsidiaries, operates as an integrated pharmaceutical company in the People’s Republic of China.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • China BCT Pharmacy Group has significant price volatility in the past 3 months.
  • China BCT Pharmacy Group's last earnings update was 2310 days ago.
  • China BCT Pharmacy Group is not covered by any analysts.

Share Price & News

How has China BCT Pharmacy Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:CNBI

0.8%

US Healthcare

1.3%

US Market


1 Year Return

n/a

OTCPK:CNBI

-8.2%

US Healthcare

2.0%

US Market

No trading data on CNBI.

No trading data on CNBI.


Share holder returns

CNBIIndustryMarket
7 Day0%0.8%1.3%
30 Day0%-1.5%3.9%
90 Day0%-0.5%3.4%
1 Yearn/a-6.8%-8.2%4.2%2.0%
3 Year-21.6%-21.6%30.2%24.9%47.2%37.6%
5 Year-93.1%-93.1%63.6%53.9%60.5%42.9%

Price Volatility Vs. Market

How volatile is China BCT Pharmacy Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is China BCT Pharmacy Group undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether China BCT Pharmacy Group is trading at an attractive price based on the cash flow it is expected to produce in the future. But as China BCT Pharmacy Group has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine China BCT Pharmacy Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through China BCT Pharmacy Group regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is China BCT Pharmacy Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China BCT Pharmacy Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has China BCT Pharmacy Group performed over the past 5 years?

0.1%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, China BCT Pharmacy Group has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is China BCT Pharmacy Group's financial position?


In this section we usually analyse China BCT Pharmacy Group's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. China BCT Pharmacy Group has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of CNBI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when China BCT Pharmacy Group's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is China BCT Pharmacy Group's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate China BCT Pharmacy Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate China BCT Pharmacy Group's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as China BCT Pharmacy Group has not reported any payouts.

Unable to verify if China BCT Pharmacy Group's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as China BCT Pharmacy Group has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of China BCT Pharmacy Group's salary, the management and board of directors tenure and is there insider trading?

9.3yrs

Average board tenure


CEO

Huitian Tang (57yo)

9.8yrs

Tenure

US$425,885

Compensation

Mr. Huitian Tang has been the Chairman and Chief Executive Officer of China BCT Pharmacy Group, Inc. since January 14, 2010 and December 30, 2009 respectively. Mr. Tang has been the President of Liuzhou Ba ...


CEO Compensation Analysis

Insufficient data for Huitian to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.

Insufficient data for Huitian to compare compensation growth.


Board Age and Tenure

9.3yrs

Average Tenure

57yo

Average Age

The tenure for the China BCT Pharmacy Group board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Huitian Tang (57yo)

    Chairman of the Board and Chief Executive Officer

    • Tenure: 9.8yrs
    • Compensation: US$425.89k
  • Xiaoyan Zhang (46yo)

    Chief Financial Officer

    • Tenure: 9.7yrs
    • Compensation: US$325.02k

Board Members

  • Kam Cheung Chin (61yo)

    Independent Director

    • Tenure: 0yrs
    • Compensation: US$16.78k
  • Yunli Lou (51yo)

    Director

    • Tenure: 8.5yrs
  • James Chiu (57yo)

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: US$16.78k
  • Huitian Tang (57yo)

    Chairman of the Board and Chief Executive Officer

    • Tenure: 9.8yrs
    • Compensation: US$425.89k
  • Xiaoyan Zhang (46yo)

    Chief Financial Officer

    • Tenure: 9.7yrs
    • Compensation: US$325.02k
  • Simon Choi (58yo)

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: US$16.78k

Company Information

China BCT Pharmacy Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China BCT Pharmacy Group, Inc.
  • Ticker: CNBI
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: US$152.616k
  • Shares outstanding: 38.15m
  • Website: https://null

Number of Employees


Location

  • China BCT Pharmacy Group, Inc.
  • No. 102, Chengzhan Road
  • Liuzhou
  • Guangxi Zhuang Province
  • 545007
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNBIOTCPK (Pink Sheets LLC)YesCommon StockUSUSDDec 2009

Biography

China BCT Pharmacy Group, Inc., through its subsidiaries, operates as an integrated pharmaceutical company in the People’s Republic of China. It operates through three segments: Pharmaceutical Distribution ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:04
End of Day Share Price2019/08/15 00:00
Earnings2013/03/31
Annual Earnings2012/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.